Deprecated!
This application is deprecated. Please use the latest version of the tool here.
Please cite:
I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni, G. Georgakilas, T. Vergoulis, I. Kanellos, I-L. Anastasopoulos, S. Maniou, K. Karathanou, D. Kalfakakou, A. Fevgas, T. Dalamagas and A. G. Hatzigeorgiou. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucl. Acids Res. (2014)
Data Download:
DIANA-TarBase v7 is available for scientific non-profit and non-commercial use! Download TarBase v7 by following this link
|
||||||||
Related Pathways
Publication year
Prediction score
Filters
Selected:
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Remove all 
Species
Method Type
Method
Regulation type
Validation type
Validated as
Source
Publication year
Prediction score
Loading... |
| Wait until the result set is completed... |
Gene name
miRNA name
Methods
Pred.Score
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257559-102257586 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257559-102257586 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255888-102255909 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257559-102257586 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257559-102257586 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
Biotinpull-down+Microarrays.Foldenrichment:6.5
Biotin-Microarrays
POSITIVE
INDIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257558-102257586 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257558-102257586 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255892-102255909 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257563-102257586 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257563-102257586 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255897-102255909 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257563-102257586 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257563-102257586 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
qPCR
NEGATIVE
INDIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249321-102249344 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249322-102249344 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249323-102249344 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257564-102257587 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257564-102257587 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251065-102251077 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249318-102249344 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257560-102257585 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257560-102257585 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250094-102250112 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251115-102251134 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249523-102249539 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249957-102249978 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257561-102257585 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257561-102257585 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257558-102257585 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257558-102257585 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255896-102255909 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257558-102257585 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. MNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257558-102257585 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102254141-102254160 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252469-102252488 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252469-102252488 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255938-102255952 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255938-102255952 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255938-102255952 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255938-102255952 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252407-102252433 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255466-102255484 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251198-102251216 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251031-102251051 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102252494-102252515 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257573-102257594 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
pSILAC
POSITIVE
INDIRECT
TarBase 6.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249494-102249501 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250103-102250122 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255894-102255917 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252463-102252488 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:102257674-102257700 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252463-102252488 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251092-102251111 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255880-102255908 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253912-102253937 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253074-102253101 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250492-102250499 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255551-102255576 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249458-102249485 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257532-102257553 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253909-102253937 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253078-102253101 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253079-102253101 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253912-102253937 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253075-102253101 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102254128-102254156 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253916-102253937 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253075-102253101 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253912-102253937 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102256238-102256258 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257531-102257553 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257680-102257699 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102234117-102234139 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250851-102250879 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257680-102257699 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253912-102253937 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253083-102253101 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251130-102251156 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249646-102249667 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249646-102249667 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249734-102249754 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257941-102257961 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249734-102249754 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102249734-102249754 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102258185-102258201 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253616-102253629 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102196865-102196888 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253916-102253936 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: WT/BaL) infected Cervical Epithelial Cell Line, HeLa derivative. Length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253075-102253101 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250385-102250408 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252472-102252492 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252472-102252492 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102254127-102254154 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257924-102257947 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257924-102257947 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102201695-102201714 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250995-102251022 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250401-102250424 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102196841-102196866 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102196841-102196866 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253831-102253859 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102256248-102256267 (UNKNOWN)
AGO2 immunoprecipitation with anti-AGO2 mAb, clone 2E12-1C9(Abnova) antibody
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255555-102255580 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255555-102255580 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255555-102255580 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255555-102255580 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253613-102253634 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255558-102255580 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255558-102255580 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102178606-102178632 (UNKNOWN)
Primary human umbilical vein endothelium. AGO2 immunoprecipitation using anti-Ago2 antibod 2A8
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102196854-102196874 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102196854-102196874 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255558-102255580 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255558-102255580 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251195-102251218 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102201684-102201708 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257574-102257599 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257574-102257599 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257573-102257599 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257573-102257599 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102196841-102196868 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102196841-102196868 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102196841-102196868 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252294-102252317 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252860-102252881 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102189848-102189871 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253735-102253754 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
Biotin pull-downs, microarrays
Biotin-Microarrays
POSITIVE
INDIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257571-102257599 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257581-102257599 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253947-102253974 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102252241-102252261 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257572-102257599 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257572-102257599 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102257572-102257599 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251428-102251451 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-618
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102028109-102028135 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
ebv-miR-BART20-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251452-102251473 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-188-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102253606-102253634 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-1913
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255024-102255045 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-3177-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102201684-102201708 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-4738-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102028109-102028136 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-17-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251303-102251331 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-218-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102197093-102197114 (UNKNOWN)
AGO2 PAR-CLIP, 2 replicates available. T1 RNase-treated samples
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
High throughput sequencing of mRNs identified 618 genes as targets of miR-218 and included both previously validated targets and many targets not predicted computationally.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-191-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102256003-102256026 (UNKNOWN)
Breast carcinoma cell line, estrogen receptor positive. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
ebv-miR-BART2-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255934-102255940 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-20b-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251303-102251331 (UNKNOWN)
Breast carcinoma cell line, Her2 amplified. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-26b-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102251778-102251803 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-29a-5p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250018-102250040 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250018-102250040 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:102250018-102250040 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-1306-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102256626-102256633 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
hsa-miR-324-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255017-102255044 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
ebv-miR-BART9
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255549-102255576 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CUX1 (hsa)
ebv-miR-BART19-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:102255582-102255600 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0